STOCK TITAN

NeuroSense Therapeutics Ltd. - $NRSN STOCK NEWS

Welcome to our dedicated page for NeuroSense Therapeutics Ltd. news (Ticker: $NRSN), a resource for investors and traders seeking the latest updates and insights on NeuroSense Therapeutics Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroSense Therapeutics Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroSense Therapeutics Ltd.'s position in the market.

Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), ensuring continued listing on the Nasdaq Stock Market. The company's CEO, Alon Ben-Noon, expressed the importance of this event as they focus on advancing PrimeC and reporting results from their collaboration with Biogen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
NRSN Announces Positive Phase 2 Clinical Trial Results for ALS Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
-
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares a review of important clinical achievements in 2023, including a statistically significant reduction in ALS disease progression in Phase 2b PARADIGM trial. The company anticipates several biomarker study results in 2024 and partnership discussions as it advances its drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirement. The company has 45 days to submit a plan to regain compliance, with a potential extension of up to 180 days if the plan is accepted. The notification does not immediately affect the listing or trading of NeuroSense's ordinary shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
none
-
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) reported a statistically significant 37.4% slowing of disease progression in ALSFRS-R with PrimeC compared to placebo, as revealed in the Phase 2b trial (PARADIGM) evaluation. The trial also showed a strong safety profile and favorable clinical results, with potential partnerships and regulatory meetings expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.94%
Tags
-
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) reported positive top-line results from its Phase 2b PARADIGM trial for PrimeC, a drug candidate for ALS. The trial demonstrated a 29% difference in favor of PrimeC in slowing disease progression, with comparable safety and tolerability to placebo. NeuroSense expects to release additional biomarker data in early 2024 and is looking forward to advancing discussions with strategic partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.16%
Tags
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) will report new data from the randomized, placebo-controlled, double-blind segment of its ongoing Phase 2b ALS trial of its lead drug candidate PrimeC. The data will include safety, tolerability endpoints, and clinical efficacy outcome measures. The conference call will be held at 8:30 am ET, and the webcast will be available for replay for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.16%
Tags
conferences clinical trial
-
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) reported topline clinical results from its Phase 2b ALS trial, with a cash runway extending into Q2 2024. The company also confirmed the FDA's CMC strategy for PrimeC, demonstrated PrimeC's outstanding effect on ALS survival, and is preparing for a Phase 2 Alzheimer's disease trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
-
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announces successful Type D meeting with the FDA for PrimeC in ALS treatment, confirming CMC strategy for Phase 3 trial and commercial launch. Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announces scientific presentations at three upcoming conferences, including the Society of Neuroscience's annual conference and the 34th International Symposium on ALS/MND. The last patient has completed the double-blind segment of PARADIGM, with clinical efficacy results expected in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
NeuroSense Therapeutics Ltd.

Nasdaq:NRSN

NRSN Rankings

NRSN Stock Data

20.97M
10.65M
28.05%
0.91%
0.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Herzliya

About NRSN

advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa